Ron Barkley, president of the Cancer Center Business Development Group, which consults with oncology providers on value-based care arrangements, shares tips.
The cost to treat cancer in the United States could reach $156 billion in 2020, according to the National Cancer Institute. And innovative medications have a significant impact on the cost of care.
CEO of a Pennsylvania-based oncology group shares how participating in a new value-based model is changing the care approach.
Healthcare systems stand to lose $6 million if burned out physicians choose to resign or work elsewhere. Here are some ways to curb burnout and its associated costs.
Genetic testing is playing a growing role in diagnosing and treating diseases, particularly when it comes to certain cancers and rheumatic conditions.
Successful CAR T-cell therapy reimbursement begins with careful payer-provider collaboration and taking these two approaches.
Shift represents growing understanding of value of genetic testing for cancers. Find out who is receiving the test and why.
Two new studies reveal that cost-restraints can keep patients from accessing life-preserving cancer drugs.
The impact of VBRs on outcomes, VBRs versus other healthcare reimbursement initiatives, and VBR successes and failures. Pfizer’s Robert Popovian, PharmD, weighs in.
Experts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.